| Coverage Initiated on Rockwell Medical (NASDAQ: RMTI) | | Print | |
| Written by Mike Havrilla | ||||
| Tuesday, 27 October 2009 09:04 | ||||
|
 As RMTI has recovered to as high as $9.39 in August 2009, shorts are becoming very active again in the stock. Failures to Deliver in RMTI have been an issue in the past as short sellers have previously been lax in complying with Regulation SHO. When failures subsided the stock rallied. The daily short volume chart of RMTI shows shorts are becoming active again in RMTI.RMTI is a small-cap bio-pharmaceutical company with a core, growing business which manufactures, sells, and distributes dialysate (which remove toxins and wastes from the blood while replacing nutrients) products to patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) receiving dialysis (which is typically conducted three times per week). The Company has a 27% share of the U.S. dialysate market with three manufacturing plants and over 16.6 million treatments provided last year. RMTI also provides ancillary products to hemodialysis (HD) providers such as blood tubing, fistula needles, dressings, cleansing agents, filtration salts, and other supplies. The Company's current line-up of dialysate products are designed to be the delivery vehicle for Soluble Ferric Pyrophosphate (SFP), which provides an opportunity for RMTI to expand upon its current market share by offering a value-added, high margin dialysate iron replacement therapy option for its customers while improving the clinical outcomes for anemic dialysis patients. The Company's core business includes the following: RenalPure (Liquid Acid and Powder Bicarbonate Concentrates), Dri-Sate (Dry Acid Concentrate and Mixing System), SteriLyte (Liquid Bicarbonate Concentrate), blood tubing sets, and fistula needles. Click here to visit the RMTI News Room landing page, which includes a compilation of digital media coverage links and downloads for the Company, including the recently published reports below. Coverage Initiated on Rockwell Medical by Buyins.Net Rockwell Medical (NASDAQ: RMTI): Mike Havrilla 9/1/09 Rockwell Medical (NASDAQ: RMTI): Wedbush Morgan 10/12/09 Disclosure: Long RMTI BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read at the bottom of / About Us / Section Add this page to your favorite Social Bookmarking websites           
Set as favorite
Bookmark
Email this
Trackback(0)
Comments (1)
henry wilf
said:
|
Starting in 2005 and through late 2007 short sellers moderately shorted 
TrackBack URI for this entry
Subscribe to this comment's feed
|
... Where is the short interest chart? Last week, I suggested a special catagory listing only PHASE 3 news. Am trying toget a release on "ONLY 13 - 15 % of PHASE 2 trials ever get to PHASE 3. Think you should be able to find this out. You might want to charge a premium for a PHASE 3 letter. (mine would be lifetime free) Henry Wilf |
|
Sign Up For Phone Alerts
